MX2012009537A - Formas solidas que comprenden un derivado de ciclopropilamida. - Google Patents

Formas solidas que comprenden un derivado de ciclopropilamida.

Info

Publication number
MX2012009537A
MX2012009537A MX2012009537A MX2012009537A MX2012009537A MX 2012009537 A MX2012009537 A MX 2012009537A MX 2012009537 A MX2012009537 A MX 2012009537A MX 2012009537 A MX2012009537 A MX 2012009537A MX 2012009537 A MX2012009537 A MX 2012009537A
Authority
MX
Mexico
Prior art keywords
solid forms
amide derivative
cyclopropyl amide
cyclopropyl
solid
Prior art date
Application number
MX2012009537A
Other languages
English (en)
Inventor
Craig D Collins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2012009537A publication Critical patent/MX2012009537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción se refiere a al menos una forma sólida de 4-{(1S, 2S)-2-[((R)-4-ciclobutil-2-metilpiperazin-1-il) carbonil]ciclopropil}benzamida. La descripción también se refiere a al menos una composición farmacéutica que comprende al menos una forma sólida descrita en la presente, a los métodos de uso de las formas sólidas y las composiciones farmacéuticas que las comprenden, y a procesos para fabricar las formas sólidas.
MX2012009537A 2010-02-18 2011-02-17 Formas solidas que comprenden un derivado de ciclopropilamida. MX2012009537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30558110P 2010-02-18 2010-02-18
PCT/SE2011/050170 WO2011102793A1 (en) 2010-02-18 2011-02-17 Solid forms comprising a cyclopropyl amide derivative

Publications (1)

Publication Number Publication Date
MX2012009537A true MX2012009537A (es) 2012-08-31

Family

ID=44370079

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009537A MX2012009537A (es) 2010-02-18 2011-02-17 Formas solidas que comprenden un derivado de ciclopropilamida.

Country Status (17)

Country Link
US (1) US20110201622A1 (es)
EP (1) EP2536701A4 (es)
JP (1) JP5746718B2 (es)
KR (1) KR20130034009A (es)
CN (1) CN103140481A (es)
AR (1) AR080203A1 (es)
AU (1) AU2011218490B9 (es)
BR (1) BR112012020780A2 (es)
CA (1) CA2789884A1 (es)
CL (1) CL2012002285A1 (es)
IL (1) IL221430A0 (es)
MX (1) MX2012009537A (es)
NZ (1) NZ602108A (es)
RU (1) RU2012136921A (es)
SG (1) SG183231A1 (es)
TW (1) TW201136898A (es)
WO (1) WO2011102793A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201446748A (zh) 2007-08-22 2014-12-16 Astrazeneca Ab 環丙基醯胺衍生物
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
EP2536702A4 (en) * 2010-02-18 2013-07-10 Astrazeneca Ab NEW CRYSTALLINE FORM OF A CYCLOPROPYLBENZAMIDE DERIVATIVE
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297170A (es) * 1963-04-04 1900-01-01
US3449427A (en) * 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) * 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) * 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
US5112818A (en) * 1989-12-29 1992-05-12 Banyu Pharmaceutical Co., Ltd. 2-(2-cyclopropylpyrrolidin-4-ylthio)carbapenhem derivatives
DE4131139A1 (de) * 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
WO2000000492A1 (fr) * 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha DERIVE D'ACIDE L-α-AMINOADIPIQUE EN POUDRE FINE, PREPARATIONS SOLIDES ORALES CONTENANT LEDIT DERIVE ET PROCEDE DE TRAITEMENT DE POUDRES EN VRAC
US6284761B1 (en) * 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
KR100849839B1 (ko) * 2001-02-23 2008-08-01 머크 앤드 캄파니 인코포레이티드 Ｎ-치환된 비-아릴-헤테로사이클릭 ｎｍｄａ/ｎｒ2ｂ 길항제 및 이를 포함하는 약제학적 조성물
USRE40794E1 (en) * 2001-09-26 2009-06-23 Merck & Co., Inc. Crystalline forms of carbapenem antibiotics and methods of preparation
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CA2479888A1 (en) * 2002-03-22 2003-10-02 Kwan-Hyung Cho New crystalline forms of (2s)-n-5-¬amino(imino)methyl|-2-thienylmethyl-1-(2r)-2-¬(carboxymethyl)amino|-3,3-diphenylpropanoyl-2-pyrrolidinecarboxamide nh2o
US20040077618A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040209858A1 (en) * 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
TW200503713A (en) * 2003-04-23 2005-02-01 Glaxo Group Ltd Novel compounds
AR045595A1 (es) * 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
CA2622760C (en) * 2005-09-16 2012-12-04 Janssen Pharmaceutica N.V. Cyclopropyl amines as modulators of the histamine h3 receptor
AU2007204426A1 (en) * 2006-01-13 2007-07-19 F. Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine H3 receptor modulators
EP2049472B1 (en) * 2006-06-23 2015-01-21 AbbVie Bahamas Ltd. Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
TW200828371A (en) * 2006-09-21 2008-07-01 Matsushita Electric Ind Co Ltd Chip-type filter
TW201446748A (zh) * 2007-08-22 2014-12-16 Astrazeneca Ab 環丙基醯胺衍生物
AU2008307195B2 (en) * 2007-10-04 2012-11-22 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
CL2009000004A1 (es) * 2008-01-15 2010-02-19 Lilly Co Eli Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
EP2536702A4 (en) * 2010-02-18 2013-07-10 Astrazeneca Ab NEW CRYSTALLINE FORM OF A CYCLOPROPYLBENZAMIDE DERIVATIVE

Also Published As

Publication number Publication date
BR112012020780A2 (pt) 2016-05-03
WO2011102793A1 (en) 2011-08-25
AU2011218490A1 (en) 2012-10-04
AU2011218490B9 (en) 2014-12-18
AU2011218490B2 (en) 2014-11-13
JP5746718B2 (ja) 2015-07-08
EP2536701A1 (en) 2012-12-26
IL221430A0 (en) 2012-10-31
US20110201622A1 (en) 2011-08-18
EP2536701A4 (en) 2014-05-07
SG183231A1 (en) 2012-09-27
NZ602108A (en) 2014-09-26
KR20130034009A (ko) 2013-04-04
RU2012136921A (ru) 2014-03-27
CN103140481A (zh) 2013-06-05
TW201136898A (en) 2011-11-01
CA2789884A1 (en) 2011-08-25
JP2013520412A (ja) 2013-06-06
AR080203A1 (es) 2012-03-21
CL2012002285A1 (es) 2013-01-25

Similar Documents

Publication Publication Date Title
JOP20180102B1 (ar) مركب صيدلاني
MY181898A (en) Heterocyclic compounds and uses thereof
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
UA109924C2 (uk) Аміди аміноінданів, які мають високу фунгіцидну активність та їх фітосанітарна композиція
MX2013012542A (es) Compuestos de amida y aplicacion farmaceutica para el mismo.
PH12014501158A1 (en) Composition comprising a shelf-life stability component
IL227815B (en) Pyrrolopyrazine-spirocyclic piperidine amide compounds, and preparations containing them and their uses
MY163083A (en) Solid forms of a pharmaceutically active substance
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX2012007507A (es) Compuestos de heteroarilo y usos de los mismos.
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
PH12015500900B1 (en) A stabilized pemetrexed formulation
EP2677029A3 (en) Methods for the manufacture of proteolytically processed polypeptides
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2013164839A3 (en) Amorphous form of apixaban, process of preparation and compositions thereof
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
AP2012006232A0 (en) New association between 4-ä3-ÄCIS-hexahydrocyclopentaÄcÜpyrrol-2(1H)-YLÜpropoxyübenzamide and an Acetylcholinesterase inhibitor, and pharmaceutical compositions containing it.
MX336333B (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida.
WO2013155338A8 (en) Substituted benzamides and their uses
IL225443A0 (en) A combined crystal of aprefitant and l-proline, preparations containing it and its uses
MX2012009537A (es) Formas solidas que comprenden un derivado de ciclopropilamida.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal